BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Jul 01, 2013
 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes

Company Bank Analyst Coverage Opinion Wk chg 6/28 cls
Allergan Inc. (NYSE:AGN) Leerink Seamus Fernandez Downgrade Market perform (from outperform) -9% $84.24
Fernandez also lowered his target to $102 from $113-$114 after FDA published draft guidance that said in vitro studies may be sufficient for determining bioequivalence of generic versions of Allergan's dry eye product Restasis 0.05% cyclosporine ophthalmic emulsion. The...

Read the full 461 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >